Arteriosclerosis and Thrombosis, Vol 11, 1129-1136, Copyright © 1991 by American Heart Association

ARTICLES

Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease

JJ Genest Jr, JR McNamara, B Upson, DN Salem, JM Ordovas, EJ Schaefer and MR Malinow
Lipid Metabolism Laboratory, US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, Mass. 02111.

Elevated plasma levels of homocyst(e)ine have been reported to be more prevalent in patients with coronary artery disease (CAD) than in controls. The purpose of this study was to determine whether this elevation was genetic. We determined homocyst(e)ine levels in 176 men with premature CAD (greater than 50% stenosis of a major epicardial coronary artery occurring before the age of 60 years) and in 255 controls free of cardiovascular disease. Homocyst(e)ine levels were higher in the CAD group compared with controls (13.9 +/- 6.7 versus 10.9 +/- 4.9 nmol/ml, p less than 0.001); in addition, 28% of CAD patients had homocyst(e)ine levels above the 90th percentile of controls. Statistical analysis revealed that homocyst(e)ine levels were not related to the presence of hypertension or diabetes, smoking, or plasma levels of lipoprotein cholesterol and apolipoproteins A-I and B. The families of 71 CAD patients were sampled (selected on the basis of availability of relatives) and included 60 spouses and 239 first-degree relatives; 370 subjects were thus sampled. Spearman correlations between probands and spouses (r = 0.264, p = 0.041) and between mean values for parent and offspring (r = 0.356, p = 0.002) for homocyst(e)ine levels indicated that homocyst(e)ine levels are in part genetically determined. In 20 families (28.2%), the proband had homocyst(e)ine levels greater than the 90th percentile; familial segregation was observed in 10 of these kindreds. Therefore, 14% of CAD patients had familial hyperhomocyst(e)inemia. In conclusion, our data suggest that plasma homocyst(e)ine is a risk factor for the development of CAD, independent of other cardiovascular risk factors, and that this elevation is in part genetically determined.

This article has been cited by other articles:

				F. A. Pac, E. Ozerol, I. H. Ozerol, I. Temel, E. Ege, S. Yologlu, N. Sezgin, K. Sahin, M. Emmiler, M. Pac, et al. Homocysteine, Lipid Profile, Nitric Oxide, Vitamin B12, and Folate Values in Patients with Premature Coronary Artery Disease and Their Children Angiology, May 1, 2005; 56(3): 253 - 257. [Abstract] [PDF]

				J.D. Kark, R. Sinnreich, I.H. Rosenberg, P.F. Jacques, and J. Selhub Plasma Homocysteine and Parental Myocardial Infarction in Young Adults in Jerusalem Circulation, June 11, 2002; 105(23): 2725 - 2729. [Abstract] [Full Text] [PDF]

				G. Schnyder, M. Roffi, Y. Flammer, R. Pin, and O.M. Hess Association of plasma homocysteine with restenosis after percutaneous coronary angioplasty Eur. Heart J., May 1, 2002; 23(9): 726 - 733. [Abstract] [Full Text] [PDF]

				E. S Ford, S J. Smith, D. F Stroup, K. K Steinberg, P. W Mueller, and S. B Thacker Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies Int. J. Epidemiol., February 1, 2002; 31(1): 59 - 70. [Abstract] [Full Text] [PDF]

				G. Schnyder, M. Roffi, R. Pin, Y. Flammer, H. Lange, F. R. Eberli, B. Meier, Z. G. Turi, and O. M. Hess Decreased Rate of Coronary Restenosis after Lowering of Plasma Homocysteine Levels N. Engl. J. Med., November 29, 2001; 345(22): 1593 - 1600. [Abstract] [Full Text] [PDF]

				E. E Delvin, R. Rozen, A. Merouani, J. Genest Jr, and M. Lambert Influence of methylenetetrahydrofolate reductase genotype, age, vitamin B-12, and folate status on plasma homocysteine in children Am. J. Clinical Nutrition, December 1, 2000; 72(6): 1469 - 1473. [Abstract] [Full Text] [PDF]

				C. De Laet, J.-C. Wautrecht, D. Brasseur, M. Dramaix, J.-M. Boeynaems, J. Decuyper, and A. Kahn Plasma homocysteine concentrations in a Belgian school-age population Am. J. Clinical Nutrition, May 1, 1999; 69(5): 968 - 972. [Abstract] [Full Text] [PDF]

				S. C. de Jong, C. D. A. Stehouwer, M. van den Berg, P. J. Kostense, D. Alders, C. Jakobs, G. Pals, and J. A. Rauwerda Determinants of Fasting and Post-Methionine Homocysteine Levels in Families Predisposed to Hyperhomocysteinemia and Premature Vascular Disease Arterioscler Thromb Vasc Biol, May 1, 1999; 19(5): 1316 - 1324. [Abstract] [Full Text] [PDF]

				M. R. Malinow, A. G. Bostom, and R. M. Krauss Homocyst(e)ine, Diet, and Cardiovascular Diseases : A Statement for Healthcare Professionals From the Nutrition Committee, American Heart Association Circulation, January 12, 1999; 99(1): 178 - 182. [Full Text] [PDF]

				D. W. Jacobsen Homocysteine and vitamins in cardiovascular disease Clin. Chem., August 1, 1998; 44(8): 1833 - 1843. [Abstract] [Full Text] [PDF]

				S. M. Grundy, G. J. Balady, M. H. Criqui, G. Fletcher, P. Greenland, L. F. Hiratzka, N. Houston-Miller, P. Kris-Etherton, H. M. Krumholz, J. LaRosa, et al. Primary Prevention of Coronary Heart Disease: Guidance From Framingham : A Statement for Healthcare Professionals From the AHA Task Force on Risk Reduction Circulation, May 19, 1998; 97(18): 1876 - 1887. [Full Text] [PDF]

				G. N. Welch and J. Loscalzo Homocysteine and Atherothrombosis N. Engl. J. Med., April 9, 1998; 338(15): 1042 - 1050. [Full Text] [PDF]

				S. C. Tyagi Homocysteine redox receptor and regulation of extracellular matrix components in vascular cells Am J Physiol Cell Physiol, February 1, 1998; 274(2): C396 - C405. [Abstract] [Full Text] [PDF]

				M. H. Moghadasian, B. M. McManus, and J. J. Frohlich Homocyst(e)ine and Coronary Artery Disease: Clinical Evidence and Genetic and Metabolic Background Arch Intern Med, November 10, 1997; 157(20): 2299 - 2308. [Abstract] [PDF]

				P. Robbins, M. Forrest, and D. Royston Hypercoagulable States Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1997; 1(4): 295 - 318. [Abstract] [PDF]

				S. C. de Jong, C. D. A. Stehouwer, A. J. C. Mackaay, M. van den Berg, E. J. Bulterijs, F. C. Visser, J. Bax, and J. A. Rauwerda High Prevalence of Hyperhomocysteinemia and Asymptomatic Vascular Disease in Siblings of Young Patients With Vascular Disease and Hyperhomocysteinemia Arterioscler Thromb Vasc Biol, November 1, 1997; 17(11): 2655 - 2662. [Abstract] [Full Text]

				M. A. Vilaseca, D. Moyano, I. Ferrer, and R. Artuch Total Homocysteine in Pediatric Patients Clin. Chem., April 1, 1997; 43(4): 690 - 692. [Full Text]

				F.E. von Eyben, J. Bech, J. K. Madsen, and F. Efsen High prevalence of smoking in young patients with acute myocardial infarction Perspectives in Public Health, June 1, 1996; 116(3): 153 - 156. [Abstract]

				F. M.T. Loehrer, C. P. Angst, W. E. Haefeli, P. P. Jordan, R. Ritz, and B. Fowler Low Whole-Blood S-Adenosylmethionine and Correlation Between 5-Methyltetrahydrofolate and Homocysteine in Coronary Artery Disease Arterioscler Thromb Vasc Biol, June 1, 1996; 16(6): 727 - 733. [Abstract] [Full Text]

				C. J. Boushey, S. A. A. Beresford, G. S. Omenn, and A. G. Motulsky A Quantitative Assessment of Plasma Homocysteine as a Risk Factor for Vascular Disease: Probable Benefits of Increasing Folic Acid Intakes JAMA, October 4, 1995; 274(13): 1049 - 1057. [Abstract] [PDF]

				P. N. Hopkins, L. L. Wu, J. Wu, S. C. Hunt, B. C. James, G. M. Vincent, and R. R. Williams Higher Plasma Homocyst(e)ine and Increased Susceptibility to Adverse Effects of Low Folate in Early Familial Coronary Artery Disease Arterioscler Thromb Vasc Biol, September 1, 1995; 15(9): 1314 - 1320. [Abstract] [Full Text]

				R. L. Nachman and R. Silverstein Hypercoagulable States Ann Intern Med, October 15, 1993; 119(8): 819 - 827. [Abstract] [Full Text]